Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.
about
The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials.
P2860
Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Requiring an amyloid-β1-42 bio ...... ore efficient clinical trials.
@en
Requiring an amyloid-β1-42 bio ...... ore efficient clinical trials.
@nl
type
label
Requiring an amyloid-β1-42 bio ...... ore efficient clinical trials.
@en
Requiring an amyloid-β1-42 bio ...... ore efficient clinical trials.
@nl
prefLabel
Requiring an amyloid-β1-42 bio ...... ore efficient clinical trials.
@en
Requiring an amyloid-β1-42 bio ...... ore efficient clinical trials.
@nl
P1476
Requiring an amyloid-β1-42 bio ...... ore efficient clinical trials.
@en
P2093
Anthony C Gamst
P304
245-6; author reply 247-9
P356
10.1016/J.JALZ.2010.12.013
P577
2011-03-01T00:00:00Z